Zanzalintinib in Men With Aggressive Variant Prostate Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a multi-center single arm phase II study to evaluate the antitumor activity of zanzalintinib 60mg orally (PO) once daily in subjects with AVPC. Zanzalintinib may continue until radiographic progression (or beyond), intolerable adverse events, or withdrawal of consent. As long as the subject is clinically stable, subjects may receive study treatment even after radiographic progression, until they are no longer clinically benefiting from the study treatment in the opinion of the treating Investigator, or they need subsequent systemic anticancer treatment or other urgent tumor directed medical intervention to prevent life-threatening complications. This study will use a 2-stage group-sequential design for enrollment. The first stage will consist of enrolling 15 subjects. No more than 5 of the first 15 subjects can have received chemotherapy in the castrate- resistant setting.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek minimum 18 lat
- •Potwierdzony histologicznie lub cytologicznie rak prostaty
- •Przerzuty nowotworu (do kości, węzłów chłonnych lub narządów wewnętrznych)
- •Kastacja (chirurgiczna lub farmakologiczna) z poziomem testosteronu poniżej 50 ng/dL
- •Progresja nowotworu mimo leczenia co najmniej jednym nowoczesnym inhibitorem receptora androgenów
- •Ogólny stan zdrowia pozwalający na uczestnictwo w badaniu (ECOG 0-2)
- •Podpisana zgoda na uczestnictwo w badaniu i udostępnienie danych medycznych
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 16, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (1)
Froedtert and The Medical College of Wisconsin
Milwaukee, United States
Trial contact
Deepak Kilari, MD
Allison Lipps
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/17/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.